{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:13:52Z","timestamp":1792005232590,"version":"4.4.0"},"reference-count":53,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,7,15]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess coronavirus disease 2019 (COVID-19) booster uptake and vaccine effectiveness (VE) in reducing COVID-19 hospitalization in persons with systemic autoimmune and rheumatic diseases (SARDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients with SARDs receiving disease-modifying antirheumatic drugs at 4 health systems in the United States were identified retrospectively. Exposures were (1) receipt of an additional dose of monovalent COVID-19 vaccine prior to January 1, 2022, with follow-up to August 31, 2022; and (2) receipt of bivalent COVID-19 vaccine between September 1, 2022 and August 31, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 201,165 patients with SARDs, 126,756 (63%) had received 1 monovalent booster as of January 1, 2022. During 94,842 person-years (PY) of follow-up, the COVID-19 hospitalization rate was 15.6 per 1000 PY among those who had received a monovalent booster vs 20.1 per 1000 PY among those who had not, with an adjusted VE of 38% (95% CI 31-44%) and a number needed to vaccinate of 267 (95% CI 230-325). Among 246,991 patients with SARDs with 233,622 PY of follow-up in the bivalent study period, the COVID-19 hospitalization rate was 7.9 per 1000 PY for the 87,906 (36%) patients who received the bivalent vaccine vs 10.2 per 1000 PY for the patients who did not. The adjusted VE of the bivalent vaccine was 32% (95% CI 24-39%) with a number needed to vaccinate of 617 (95% CI 500-838).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>COVID-19 booster vaccinations provided significant protection against severe COVID-19 in persons with SARDs. Thus, increasing vaccine uptake should be prioritized in this high-risk immunocompromised population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0535","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T12:20:19Z","timestamp":1754050819000},"page":"1288-1301","source":"Crossref","is-referenced-by-count":6,"title":["COVID-19 Vaccine Booster Uptake and Effectiveness Among Persons With Systemic Autoimmune and Rheumatic Diseases"],"prefix":"10.3899","volume":"52","author":[{"given":"Yonah C.","family":"Ziemba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Elkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Kazemian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigid M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinnah","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl B.","family":"Schleicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal A.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Zidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Kushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C.","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1630-5733","authenticated-orcid":false,"given":"Jacek","family":"Skarbinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-1093","authenticated-orcid":false,"given":"James M.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2025120106151102000_52.12.1288.1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2024.09.005","article-title":"The impact of coronavirus disease 2019 on patients living with rheumatic diseases","volume":"51","author":"Kohn","year":"2025","journal-title":"Rheum Dis Clin North Am"},{"key":"2025120106151102000_52.12.1288.2","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/art.41800","article-title":"Risk of COVID-19 in rheumatoid arthritis: a national Veterans Affairs matched cohort study in at-risk individuals","volume":"73","author":"England","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025120106151102000_52.12.1288.3","doi-asserted-by":"crossref","first-page":"SI59","DOI":"10.1093\/rheumatology\/keaa897","article-title":"Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark","volume":"60","author":"Cordtz","year":"2021","journal-title":"Rheumatology"},{"key":"2025120106151102000_52.12.1288.4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11926-023-01111-y","article-title":"Considerations for pharmacologic management of rheumatoid arthritis in the COVID-19 era: a narrative review","volume":"25","author":"Venkat","year":"2023","journal-title":"Curr Rheumatol Rep"},{"key":"2025120106151102000_52.12.1288.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-1214"},{"key":"2025120106151102000_52.12.1288.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0357"},{"key":"2025120106151102000_52.12.1288.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0742"},{"key":"2025120106151102000_52.12.1288.8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.rdc.2024.09.006","article-title":"Considerations for coronavirus disease 2019 vaccination among B-cell-depleted patients","volume":"51","author":"Ammitzb\u00f8ll","year":"2025","journal-title":"Rheum Dis Clin North Am"},{"key":"2025120106151102000_52.12.1288.9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41584-022-00755-x","article-title":"COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations","volume":"18","author":"Grainger","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025120106151102000_52.12.1288.10","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/vaccines10050800","article-title":"Vaccination for the prevention of infection among immunocompromised patients: a concise review of recent systematic reviews","volume":"10","author":"See See","year":"2022","journal-title":"Vaccines"},{"key":"2025120106151102000_52.12.1288.11","doi-asserted-by":"crossref","first-page":"e180750","DOI":"10.1172\/jci.insight.180750","article-title":"Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases","volume":"9","author":"Anderson","year":"2024","journal-title":"JCI Insight"},{"key":"2025120106151102000_52.12.1288.12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002187"},{"key":"2025120106151102000_52.12.1288.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0006"},{"key":"2025120106151102000_52.12.1288.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2025120106151102000_52.12.1288.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"2025120106151102000_52.12.1288.16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/rheumatology\/keaa483","article-title":"The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice","volume":"60","author":"Liew","year":"2021","journal-title":"Rheumatology"},{"key":"2025120106151102000_52.12.1288.17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41584-020-0418-0","article-title":"The COVID-19 global rheumatology alliance: collecting data in a pandemic","volume":"16","author":"Robinson","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025120106151102000_52.12.1288.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221824"},{"key":"2025120106151102000_52.12.1288.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220870"},{"key":"2025120106151102000_52.12.1288.20","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00272-2"},{"key":"2025120106151102000_52.12.1288.21","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.15585\/mmwr.mm7349a2","article-title":"Use of additional doses of 2024-2025 COVID-19 vaccine for adults aged \u226565 years and persons aged \u22656 months with moderate or severe immunocompromise: recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2024","volume":"73","author":"Roper","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025120106151102000_52.12.1288.22","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/art.42372","article-title":"American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5","volume":"75","author":"Curtis","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025120106151102000_52.12.1288.23","doi-asserted-by":"crossref","first-page":"ofac171","DOI":"10.1093\/ofid\/ofac171","article-title":"Mission, organization, and future direction of the serological sciences network for COVID-19 (SeroNet) epidemiologic cohort studies","volume":"9","author":"Figueiredo","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025120106151102000_52.12.1288.24","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00006-1"},{"key":"2025120106151102000_52.12.1288.25","doi-asserted-by":"crossref","unstructured":"Skarbinski J , Elkin EP , Ziemba YC , . COVID-19 vaccine booster uptake and effectiveness among persons with cancer in the United States. JAMA Oncol 2025 July 17 (Epub ahead of print).","DOI":"10.1001\/jamaoncol.2025.2020"},{"key":"2025120106151102000_52.12.1288.26","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7044e2"},{"key":"2025120106151102000_52.12.1288.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.03.012"},{"key":"2025120106151102000_52.12.1288.28","doi-asserted-by":"publisher","DOI":"10.1159\/000521288"},{"key":"2025120106151102000_52.12.1288.29","unstructured":"Rothman KJ , Greenland S , editors Chapter 32. Meta-analysis. In: Modern epidemiology, 2nd edition. Philadelphia: Lippincott-Raven Publishers; 1998:643-73."},{"key":"2025120106151102000_52.12.1288.30","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0024-z"},{"key":"2025120106151102000_52.12.1288.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198806303182605"},{"key":"2025120106151102000_52.12.1288.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.11.052"},{"key":"2025120106151102000_52.12.1288.33","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7037e1"},{"key":"2025120106151102000_52.12.1288.34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003992"},{"key":"2025120106151102000_52.12.1288.35","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/S2666-5247(22)00390-1","article-title":"Efficacy of SARS-CoV-2 vaccines and the dose\u2014response relationship with three major antibodies: a systematic review and meta-analysis of randomized controlled trials","volume":"4","author":"Yang","year":"2023","journal-title":"Lancet Microbe"},{"key":"2025120106151102000_52.12.1288.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01699-1"},{"key":"2025120106151102000_52.12.1288.37","doi-asserted-by":"crossref","first-page":"100447","DOI":"10.1016\/j.jvacx.2024.100447","article-title":"Effectiveness of monovalent COVID-19 booster\/additional vaccine doses in the United States","volume":"16","author":"Layton","year":"2024","journal-title":"Vaccin X"},{"key":"2025120106151102000_52.12.1288.38","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005114"},{"key":"2025120106151102000_52.12.1288.39","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.vaccine.2024.04.049","article-title":"A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants","volume":"42","author":"Song","year":"2024","journal-title":"Vaccine"},{"key":"2025120106151102000_52.12.1288.40","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1186\/s12879-025-10866-x","article-title":"Long term bivalent mRNA vaccine effectiveness against COVID-19 hospitalisations and deaths in Portugal: a cohort study based on electronic health records","volume":"25","author":"Machado","year":"2025","journal-title":"BMC Infect Dis"},{"key":"2025120106151102000_52.12.1288.41","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7221a3"},{"key":"2025120106151102000_52.12.1288.42","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1093\/rheumatology\/kead064","article-title":"Fourth dose of BNT162b2 vaccine for patients with autoimmune rheumatic diseases in a nationwide setting","volume":"62","author":"Bieber","year":"2023","journal-title":"Rheumatology"},{"key":"2025120106151102000_52.12.1288.43","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2589-7500(24)00021-9","article-title":"Machine learning to understand risks for severe COVID-19 outcomes: a retrospective cohort study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US health-care system","volume":"6","author":"Wei","year":"2024","journal-title":"Lancet Digit Health"},{"key":"2025120106151102000_52.12.1288.44","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225162"},{"key":"2025120106151102000_52.12.1288.45","doi-asserted-by":"publisher","DOI":"10.1097\/01.MLR.0000020942.47004.03"},{"key":"2025120106151102000_52.12.1288.46","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.535661"},{"key":"2025120106151102000_52.12.1288.47","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/CCI.19.00114","article-title":"Workflow differences affect data accuracy in oncologic EHRs: a first step toward detangling the diagnosis data babel","volume":"4","author":"Diaz-Garelli","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"key":"2025120106151102000_52.12.1288.48","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.15585\/mmwr.mm7132e1","article-title":"Vital signs: hepatitis C treatment among insured adults\u2014United States, 2019-2020. Vital Signs","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025120106151102000_52.12.1288.49","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7131a3"},{"key":"2025120106151102000_52.12.1288.50","doi-asserted-by":"crossref","unstructured":"Hendrix N , Sidky H , Sahner DK ; N3C Consortium . Influence of prior SARS-CoV-2 infection on COVID-19 severity: evidence from the National COVID Cohort Collaborative. medRxiv 2024 Jan 26. [Preprint. Accessed August 11, 2025.] Available from: doi.org\/10.1101\/2023.08.03.23293612","DOI":"10.1101\/2023.08.03.23293612"},{"key":"2025120106151102000_52.12.1288.51","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12874-023-01839-2","article-title":"Data quality considerations for evaluating COVID-19 treatments using real world data: learnings from the National COVID Cohort Collaborative (N3C)","volume":"23","author":"Sidky","year":"2023","journal-title":"BMC Med Res Methodol"},{"key":"2025120106151102000_52.12.1288.52","doi-asserted-by":"crossref","first-page":"ofaf021","DOI":"10.1093\/ofid\/ofaf021","article-title":"Coronavirus disease 2019 (COVID-19) real world data infrastructure: a big data resource for study of the impact of COVID-19 in patient populations with immunocompromising conditions","volume":"12","author":"Crawford","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2025120106151102000_52.12.1288.53","first-page":"100461","article-title":"COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada","volume":"20","author":"Bahremand","year":"2023","journal-title":"Lancet Reg Health Am"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:15:43Z","timestamp":1764598543000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.3899\/jrheum.2025-0535"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0535","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}